Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, 43291-43293 [E7-15149]
Download as PDF
<![CDATA[
43291
Federal Register / Vol. 72, No. 149 / Friday, August 3, 2007 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–1243.
Proposed Project: Substance Abuse
Prevention and Treatment Block Grant
Synar Report Format, FFY 2008–2010—
(OMB No. 0930–0222)—Revision
Section 1926 of the Public Health
Service Act [42 U.S.C. 300x–26]
stipulates that funding Substance Abuse
Prevention and Treatment (SAPT) Block
Grant agreements for alcohol and drug
abuse programs for fiscal year 1994 and
subsequent fiscal years require States to
have in effect a law providing that it is
unlawful for any manufacturer, retailer,
or distributor of tobacco products to sell
or distribute any such product to any
individual under the age of 18. This
section further requires that States
approved by OMB under control
number 0930–0163, and require that
each State submit an annual Synar
report to the Secretary describing their
progress in complying with section 1926
of the PHS Act. The Synar report, due
December 31 following the fiscal year
for which the State is reporting,
describes the results of the inspections
and the activities carried out by the
State to enforce the required law; the
success the State has achieved in
reducing the availability of tobacco
products to individuals under the age of
18; and the strategies to be utilized by
the State for enforcing such law during
the fiscal year for which the grant is
sought.
SAMHSA’s Center for Substance
Abuse Prevention will request OMB
approval of revisions to the current
report format associated with section
1926 (42 U.S.C. 300x–26). The report
format is changing significantly. Any
changes in either formatting or content
are being made to simplify the reporting
process for the States and to clarify the
information as the States report it; both
outcomes will facilitate consistent,
credible, and efficient monitoring of
Synar compliance across the States and
will reduce the reporting burden by the
States. All of the information required
in the new report format is already
being collected by the States.
conduct annual, random, unannounced
inspections to ensure compliance with
the law; that the State submit annually
a report describing the results of the
inspections, describing the activities
carried out by the State to enforce the
required law, describing the success the
State has achieved in reducing the
availability of tobacco products to
individuals under the age of 18, and
describing the strategies to be utilized
by the State for enforcing such law
during the fiscal year for which the
grant is sought.
Before making an award to a State
under the SAPT Block Grant, the
Secretary must make a determination
that the State has maintained
compliance with these requirements. If
a determination is made that the State
is not in compliance, penalties shall be
applied. Penalties ranged from 10
percent of the Block Grant in applicable
year 1 (FFY 1997 SAPT Block Grant
Applications) to 40 percent in
applicable year 4 (FFY 2000 SAPT
Block Grant Applications) and
subsequent years. Respondents include
the 50 States, the District of Columbia,
the Commonwealth of Puerto Rico, the
U.S. Virgin Islands, Guam, American
Samoa, the Commonwealth of the
Northern Mariana Islands, Palau,
Micronesia, and the Marshall Islands.
Regulations that implement this
legislation are at 45 CFR 96.130, are
ANNUAL REPORTING BURDEN
Responses
per
respondents
Number of
respondents1
45 CFR citation
Hours per
response
Total hour
burden
Annual Report (Section 1—States and Territories) 96.130(e)(1–3) ................
State Plan (Section II–States and Territories) 96.130(e)(4,5)96.130(g) .........
59
59
1
1
15
3
885
177
Total ..........................................................................................................
59
........................
........................
1,062
mstockstill on PROD1PC66 with NOTICES
1
Red Lake Indian Tribe is not subject to tobacco requirements.
Written comments and
recommendations concerning the
proposed information collection should
be sent by September 4, 2007 to:
SAMHSA Desk Officer, Human
Resources and Housing Branch, Office
of Management and Budget, New
Executive Office Building, Room 10235,
Washington, DC 20503; due to potential
delays in OMB’s receipt and processing
of mail sent through the U.S. Postal
Service, respondents are encouraged to
submit comments by fax to: 202–395–
6974.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: July 31, 2007.
Elaine Parry,
Acting Director, Office of Program Services.
[FR Doc. E7–15143 Filed 8–2–07; 8:45 am]
SUMMARY: The Department of Health and
Human Services (HHS) notifies Federal
agencies of the laboratories currently
certified to meet the standards of
Subpart C of the Mandatory Guidelines
BILLING CODE 4162–20–P
VerDate Aug<31>2005
18:17 Aug 02, 2007
Jkt 211001
Substance Abuse and Mental Health
Services Administration
Current List of Laboratories Which
Meet Minimum Standards To Engage in
Urine Drug Testing for Federal
Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register on
April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908),
on September 30, 1997 (62 FR 51118),
and on April 13, 2004 (69 FR 19644).
A notice listing all currently certified
laboratories is published in the Federal
Register during the first week of each
month. If any laboratory’s certification
is suspended or revoked, the laboratory
will be omitted from subsequent lists
until such time as it is restored to full
certification under the Mandatory
Guidelines.
E:\FR\FM\03AUN1.SGM
03AUN1
mstockstill on PROD1PC66 with NOTICES
43292
Federal Register / Vol. 72, No. 149 / Friday, August 3, 2007 / Notices
If any laboratory has withdrawn from
the HHS National Laboratory
Certification Program (NLCP) during the
past month, it will be listed at the end,
and will be omitted from the monthly
listing thereafter.
This notice is also available on the
Internet at https://
www.workplace.samhsa.gov and https://
www.drugfreeworkplace.gov.
FOR FURTHER INFORMATION CONTACT: Mrs.
Giselle Hersh or Dr. Walter Vogl,
Division of Workplace Programs,
SAMHSA/CSAP, Room 2–1035, 1 Choke
Cherry Road, Rockville, Maryland
20857; 240–276–2600 (voice), 240–276–
2610 (fax).
SUPPLEMENTARY INFORMATION: The
Mandatory Guidelines were developed
in accordance with Executive Order
12564 and section 503 of Pub. L. 100–
71. Subpart C of the Mandatory
Guidelines, ‘‘Certification of
Laboratories Engaged in Urine Drug
Testing for Federal Agencies,’’ sets strict
standards that laboratories must meet in
order to conduct drug and specimen
validity tests on urine specimens for
Federal agencies. To become certified,
an applicant laboratory must undergo
three rounds of performance testing plus
an on-site inspection. To maintain that
certification, a laboratory must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories which claim to be in the
applicant stage of certification are not to
be considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A laboratory
must have its letter of certification from
HHS/SAMHSA (formerly: HHS/NIDA)
which attests that it has met minimum
standards.
In accordance with Subpart C of the
Mandatory Guidelines dated April 13,
2004 (69 FR 19644), the following
laboratories meet the minimum
standards to conduct drug and specimen
validity tests on urine specimens:
ACL Laboratories, 8901 W. Lincoln
Ave., West Allis, WI 53227, 414–328–
7840/800–877–7016. (Formerly:
Bayshore Clinical Laboratory).
ACM Medical Laboratory, Inc., 160
Elmgrove Park, Rochester, NY 14624,
585–429–2264.
Advanced Toxicology Network, 3560
Air Center Cove, Suite 101, Memphis,
TN 38118, 901–794–5770/888–290–
1150.
Aegis Sciences Corporation, 345 Hill
Ave., Nashville, TN 37210, 615–255–
2400. (Formerly: Aegis Analytical
Laboratories, Inc.).
Baptist Medical Center-Toxicology
Laboratory, 9601 I–630, Exit 7, Little
VerDate Aug<31>2005
18:17 Aug 02, 2007
Jkt 211001
Rock, AR 72205–7299, 501–202–2783.
(Formerly: Forensic Toxicology
Laboratory Baptist Medical Center).
Clinical Reference Lab, 8433 Quivira
Road, Lenexa, KS 66215–2802, 800–
445–6917.
Diagnostic Services, Inc., dba DSI,
12700 Westlinks Drive, Fort Myers, FL
33913, 239–561–8200/800–735–5416.
Doctors Laboratory, Inc., 2906 Julia
Drive, Valdosta, GA 31602, 229–671–
2281.
DrugScan, Inc., P.O. Box 2969, 1119
Mearns Road, Warminster, PA 18974,
215–674–9310.
Dynacare Kasper Medical
Laboratories*, 10150–102 St., Suite 200,
Edmonton, Alberta, Canada T5J 5E2,
780–451–3702/800–661–9876.
ElSohly Laboratories, Inc., 5
Industrial Park Drive, Oxford, MS
38655, 662–236–2609.
Gamma-Dynacare Medical
Laboratories*, A Division of the
Gamma-Dynacare Laboratory
Partnership, 245 Pall Mall Street,
London, ONT, Canada N6A 1P4, 519–
679–1630.
Kroll Laboratory Specialists, Inc.,
1111 Newton St., Gretna, LA 70053,
504–361–8989/800–433–3823.
(Formerly: Laboratory Specialists, Inc.).
Kroll Laboratory Specialists, Inc., 450
Southlake Blvd., Richmond, VA 23236,
804–378–9130. (Formerly: Scientific
Testing Laboratories, Inc.; Kroll
Scientific Testing Laboratories, Inc.).
Laboratory Corporation of America
Holdings, 7207 N. Gessner Road,
Houston, TX 77040, 713–856–8288/
800–800–2387.
Laboratory Corporation of America
Holdings, 69 First Ave., Raritan, NJ
08869, 908–526–2400/800–437–4986.
(Formerly: Roche Biomedical
Laboratories, Inc.).
Laboratory Corporation of America
Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709, 919–
572–6900/800–833–3984. (Formerly:
LabCorp Occupational Testing Services,
Inc., CompuChem Laboratories, Inc.;
CompuChem Laboratories, Inc., A
Subsidiary of Roche Biomedical
Laboratory; Roche CompuChem
Laboratories, Inc., A Member of the
Roche Group).
Laboratory Corporation of America
Holdings, 13112 Evening Creek Drive,
Suite 100, San Diego, CA 92128, 858–
668–3710/800–882–7272. (Formerly:
Poisonlab, Inc.).
Laboratory Corporation of America
Holdings, 550 17th Ave., Suite 300,
Seattle, WA 98122, 206–923–7020/800–
898–0180. (Formerly: DrugProof,
Division of Dynacare/Laboratory of
Pathology, LLC; Laboratory of Pathology
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
of Seattle, Inc.; DrugProof, Division of
Laboratory of Pathology of Seattle, Inc.).
Laboratory Corporation of America
Holdings, 1120 Main Street, Southaven,
MS 38671, 866–827–8042/800–233–
6339. (Formerly: LabCorp Occupational
Testing Services, Inc.; MedExpress/
National Laboratory Center).
LabOne, Inc. d/b/a Quest Diagnostics,
10101 Renner Blvd., Lenexa, KS 66219,
913–888–3927/800–873–8845.
(Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for
Laboratory Services, a Division of
LabOne, Inc.).
Marshfield Laboratories, Forensic
Toxicology Laboratory, 1000 North Oak
Ave., Marshfield, WI 54449, 715–389–
3734/800–331–3734.
MAXXAM Analytics Inc.*, 6740
Campobello Road, Mississauga, ON,
Canada L5N 2L8, 905–817–5700.
(Formerly: NOVAMANN (Ontario),
Inc.).
MedTox Laboratories, Inc., 402 W.
County Road D, St. Paul, MN 55112,
651–636–7466/800–832–3244.
Meriter Laboratories, 36 South Brooks
St., Madison, WI 53715, 608–267–6225.
(Formerly: General Medical
Laboratories).
MetroLab-Legacy Laboratory Services,
1225 NE 2nd Ave., Portland, OR 97232,
503–413–5295 / 800–950–5295.
Minneapolis Veterans Affairs Medical
Center, Forensic Toxicology Laboratory,
1 Veterans Drive, Minneapolis, MN
55417, 612–725–2088.
National Toxicology Laboratories,
Inc., 1100 California Ave., Bakersfield,
CA 93304, 661–322–4250/800–350–
3515.
One Source Toxicology Laboratory,
Inc., 1213 Genoa-Red Bluff, Pasadena,
TX 77504, 888–747–3774. (Formerly:
University of Texas Medical Branch,
Clinical Chemistry Division; UTMB
Pathology-Toxicology Laboratory).
Oregon Medical Laboratories, 123
International Way, Springfield, OR
97477, 541–341–8092.
Pacific Toxicology Laboratories, 9348
DeSoto Ave., Chatsworth, CA 91311,
800–328–6942. (Formerly: Centinela
Hospital Airport Toxicology
Laboratory).
Pathology Associates Medical
Laboratories, 110 West Cliff Dr.,
Spokane, WA 99204, 509–755–8991/
800–541–7891x7.
Phamatech, Inc., 10151 Barnes
Canyon Road, San Diego, CA 92121,
858–643–5555.
Physicians Reference Laboratory,
7800 West 110th St., Overland Park, KS
66210, 913–339–0372/800–821–3627.
Quest Diagnostics Incorporated, 3175
Presidential Dr., Atlanta, GA 30340,
770–452–1590/800–729–6432.
E:\FR\FM\03AUN1.SGM
03AUN1
mstockstill on PROD1PC66 with NOTICES
Federal Register / Vol. 72, No. 149 / Friday, August 3, 2007 / Notices
(Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline BioScience Laboratories).
Quest Diagnostics Incorporated, 400
Egypt Road, Norristown, PA 19403,
610–631–4600/877–642–2216.
(Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline BioScience Laboratories).
Quest Diagnostics Incorporated, 7600
Tyrone Ave., Van Nuys, CA 91405, 866–
370–6699/818–989–2521, (Formerly:
SmithKline Beecham Clinical
Laboratories).
S.E.D. Medical Laboratories, 5601
Office Blvd., Albuquerque, NM 87109,
505–727–6300/800–999–5227.
South Bend Medical Foundation, Inc.,
530 N. Lafayette Blvd., South Bend, IN
46601, 574–234–4176 x276.
Southwest Laboratories, 4645 E.
Cotton Center Boulevard, Suite 177,
Phoenix, AZ 85040, 602–438–8507/800–
279–0027.
Sparrow Health System, Toxicology
Testing Center, St. Lawrence Campus,
1210 W. Saginaw, Lansing, MI 48915,
517–364–7400. (Formerly: St. Lawrence
Hospital & Healthcare System).
St. Anthony Hospital Toxicology
Laboratory, 1000 N. Lee St., Oklahoma
City, OK 73101, 405–272–7052.
Toxicology & Drug Monitoring
Laboratory, University of Missouri
Hospital & Clinics, 301 Business Loop
70 West, Suite 208, Columbia, MO
65203, 573–882–1273.
Toxicology Testing Service, Inc., 5426
N.W. 79th Ave., Miami, FL 33166, 305–
593–2260.
US Army Forensic Toxicology Drug
Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755–5235,
301–677–7085.
*The Standards Council of Canada
(SCC) voted to end its Laboratory
Accreditation Program for Substance
Abuse (LAPSA) effective May 12, 1998.
Laboratories certified through that
program were accredited to conduct
forensic urine drug testing as required
by U.S. Department of Transportation
(DOT) regulations. As of that date, the
certification of those accredited
Canadian laboratories will continue
under DOT authority. The responsibility
for conducting quarterly performance
testing plus periodic on-site inspections
of those LAPSA-accredited laboratories
was transferred to the U.S. HHS, with
the HHS’ NLCP contractor continuing to
have an active role in the performance
testing and laboratory inspection
processes. Other Canadian laboratories
wishing to be considered for the NLCP
may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to
be qualified, HHS will recommend that
VerDate Aug<31>2005
18:17 Aug 02, 2007
Jkt 211001
43293
DOT certify the laboratory (Federal
Register, July 16, 1996) as meeting the
minimum standards of the Mandatory
Guidelines published in the Federal
Register on April 13, 2004 (69 FR
19644). After receiving DOT
certification, the laboratory will be
included in the monthly list of HHScertified laboratories and participate in
the NLCP certification maintenance
program.
DEPARTMENT OF THE INTERIOR
Elaine Parry,
Acting Director, Office of Program Services,
SAMHSA.
[FR Doc. E7–15149 Filed 8–2–07; 8:45 am]
SUMMARY: In accordance with the
provisions of the Rocky Flats National
Wildlife Refuge Act of 2001 (Pub. L.
107–107, 115 Stat. 1012, 1380–1387)
hereinafter referred to as the ‘‘Refuge
Act,’’ the Secretary of Energy has
transferred primary administrative
jurisdiction over approximately
3,953.03 acres of real property at the
former Rocky Flats Environmental
Technology Site (RFETS), Jefferson and
Boulder Counties, Colorado, to the
Secretary of the Interior.
Pursuant to section 3177(d) of the
‘‘Refuge Act,’’ the Secretary of the
Interior hereby provides notice of the
establishment of the Rocky Flats
National Wildlife Refuge (Refuge).
The ‘‘Refuge Act’’ provides that
following environmental remediation of
RFETS, under the Comprehensive
Environmental Response,
Compensation, and Liability Act of
1980, and other applicable provisions of
law, the Secretary of Energy shall
transfer administrative jurisdiction over
real property comprising the Refuge to
the Secretary of the Interior for
establishment of the Rocky Flats
National Wildlife Refuge.
Environmental remediation of the
Rocky Flats National Priorities List Site
has been completed, except for on-going
operations and maintenance, pursuant
to a Record of Decision signed by the
Department of Energy, Environmental
Protection Agency (EPA) and the State
of Colorado in 2006. On May 25, 2007,
the Regional Administrator of the EPA
published notice in the Federal Register
announcing deletion of the Peripheral
Operable Unit and Operable Unit 3. On
June 11, 2007, the Administrator of the
EPA, acting through the Regional
Administrator, Region 8, EPA, certified
to the Secretary of Energy and the
Secretary of the Interior that all
response actions for the deleted areas
have been completed, except for the
operation and maintenance associated
with response acting and that all
response actions are operating properly
and successfully.
Pursuant to the ‘‘Refuge Act,’’
administrative jurisdictions over
portions of the deleted Peripheral
Operable Unit, totaling approximately
BILLING CODE 4160–20–P
DEPARTMENT OF HOUSING AND
URBAN DEVELOPMENT
[Docket No. FR–5125–N–31]
Federal Property Suitable as Facilities
To Assist the Homeless
Office of the Assistant
Secretary for Community Planning and
Development, HUD.
ACTION: Notice.
AGENCY:
SUMMARY: This Notice identifies
unutilized, underutilized, excess, and
surplus Federal property reviewed by
HUD for suitability for possible use to
assist the homeless.
EFFECTIVE DATE: August 3, 2007.
FOR FURTHER INFORMATION CONTACT:
Kathy Ezzell, Department of Housing
and Urban Development, Room 7262,
451 Seventh Street, SW., Washington,
DC 20410; telephone (202) 708–1234;
TTY number for the hearing- and
speech-impaired (202) 708–2565, (these
telephone numbers are not toll-free), or
call the toll-free Title V information line
at 1–800–927–7588.
SUPPLEMENTARY INFORMATION: In
accordance with the December 12, 1988
court order in National Coalition for the
Homeless v. Veterans Administration,
No. 88–2503–OG (D.D.C.), HUD
publishes a Notice, on a weekly basis,
identifying unutilized, underutilized,
excess and surplus Federal buildings
and real property that HUD has
reviewed for suitability for use to assist
the homeless. Today’s Notice is for the
purpose of announcing that no
additional properties have been
determined suitable or unsuitable this
week.
Dated: July 26, 2007.
Mark R. Johnston,
Deputy Assistant Secretary for Special Needs.
[FR Doc. E7–14706 Filed 8–2–07; 8:45 am]
BILLING CODE 4210–67–P
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
Fish and Wildlife Service
Establishment of Rocky Flats National
Wildlife Refuge, Colorado
Fish and Wildlife Service,
Interior.
ACTION: Establishment of Rocky Flats
National Wildlife Refuge.
AGENCY:
E:\FR\FM\03AUN1.SGM
03AUN1
]]>Agencies
[Federal Register Volume 72, Number 149 (Friday, August 3, 2007)]
[Notices]
[Pages 43291-43293]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-15149]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Current List of Laboratories Which Meet Minimum Standards To
Engage in Urine Drug Testing for Federal Agencies
AGENCY: Substance Abuse and Mental Health Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services (HHS) notifies
Federal agencies of the laboratories currently certified to meet the
standards of Subpart C of the Mandatory Guidelines for Federal
Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory
Guidelines were first published in the Federal Register on April 11,
1988 (53 FR 11970), and subsequently revised in the Federal Register on
June 9, 1994 (59 FR 29908), on September 30, 1997 (62 FR 51118), and on
April 13, 2004 (69 FR 19644).
A notice listing all currently certified laboratories is published
in the Federal Register during the first week of each month. If any
laboratory's certification is suspended or revoked, the laboratory will
be omitted from subsequent lists until such time as it is restored to
full certification under the Mandatory Guidelines.
[[Page 43292]]
If any laboratory has withdrawn from the HHS National Laboratory
Certification Program (NLCP) during the past month, it will be listed
at the end, and will be omitted from the monthly listing thereafter.
This notice is also available on the Internet at https://
www.workplace.samhsa.gov and https://www.drugfreeworkplace.gov.
FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh or Dr. Walter Vogl,
Division of Workplace Programs, SAMHSA/CSAP, Room 2-1035, 1 Choke
Cherry Road, Rockville, Maryland 20857; 240-276-2600 (voice), 240-276-
2610 (fax).
SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were developed in
accordance with Executive Order 12564 and section 503 of Pub. L. 100-
71. Subpart C of the Mandatory Guidelines, ``Certification of
Laboratories Engaged in Urine Drug Testing for Federal Agencies,'' sets
strict standards that laboratories must meet in order to conduct drug
and specimen validity tests on urine specimens for Federal agencies. To
become certified, an applicant laboratory must undergo three rounds of
performance testing plus an on-site inspection. To maintain that
certification, a laboratory must participate in a quarterly performance
testing program plus undergo periodic, on-site inspections.
Laboratories which claim to be in the applicant stage of
certification are not to be considered as meeting the minimum
requirements described in the HHS Mandatory Guidelines. A laboratory
must have its letter of certification from HHS/SAMHSA (formerly: HHS/
NIDA) which attests that it has met minimum standards.
In accordance with Subpart C of the Mandatory Guidelines dated
April 13, 2004 (69 FR 19644), the following laboratories meet the
minimum standards to conduct drug and specimen validity tests on urine
specimens:
ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414-
328-7840/800-877-7016. (Formerly: Bayshore Clinical Laboratory).
ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY
14624, 585-429-2264.
Advanced Toxicology Network, 3560 Air Center Cove, Suite 101,
Memphis, TN 38118, 901-794-5770/888-290-1150.
Aegis Sciences Corporation, 345 Hill Ave., Nashville, TN 37210,
615-255-2400. (Formerly: Aegis Analytical Laboratories, Inc.).
Baptist Medical Center-Toxicology Laboratory, 9601 I-630, Exit 7,
Little Rock, AR 72205-7299, 501-202-2783. (Formerly: Forensic
Toxicology Laboratory Baptist Medical Center).
Clinical Reference Lab, 8433 Quivira Road, Lenexa, KS 66215-2802,
800-445-6917.
Diagnostic Services, Inc., dba DSI, 12700 Westlinks Drive, Fort
Myers, FL 33913, 239-561-8200/800-735-5416.
Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602,
229-671-2281.
DrugScan, Inc., P.O. Box 2969, 1119 Mearns Road, Warminster, PA
18974, 215-674-9310.
Dynacare Kasper Medical Laboratories*, 10150-102 St., Suite 200,
Edmonton, Alberta, Canada T5J 5E2, 780-451-3702/800-661-9876.
ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS
38655, 662-236-2609.
Gamma-Dynacare Medical Laboratories*, A Division of the Gamma-
Dynacare Laboratory Partnership, 245 Pall Mall Street, London, ONT,
Canada N6A 1P4, 519-679-1630.
Kroll Laboratory Specialists, Inc., 1111 Newton St., Gretna, LA
70053, 504-361-8989/800-433-3823. (Formerly: Laboratory Specialists,
Inc.).
Kroll Laboratory Specialists, Inc., 450 Southlake Blvd., Richmond,
VA 23236, 804-378-9130. (Formerly: Scientific Testing Laboratories,
Inc.; Kroll Scientific Testing Laboratories, Inc.).
Laboratory Corporation of America Holdings, 7207 N. Gessner Road,
Houston, TX 77040, 713-856-8288/800-800-2387.
Laboratory Corporation of America Holdings, 69 First Ave., Raritan,
NJ 08869, 908-526-2400/800-437-4986. (Formerly: Roche Biomedical
Laboratories, Inc.).
Laboratory Corporation of America Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709, 919-572-6900/800-833-3984. (Formerly:
LabCorp Occupational Testing Services, Inc., CompuChem Laboratories,
Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical
Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche
Group).
Laboratory Corporation of America Holdings, 13112 Evening Creek
Drive, Suite 100, San Diego, CA 92128, 858-668-3710/800-882-7272.
(Formerly: Poisonlab, Inc.).
Laboratory Corporation of America Holdings, 550 17th Ave., Suite
300, Seattle, WA 98122, 206-923-7020/800-898-0180. (Formerly:
DrugProof, Division of Dynacare/Laboratory of Pathology, LLC;
Laboratory of Pathology of Seattle, Inc.; DrugProof, Division of
Laboratory of Pathology of Seattle, Inc.).
Laboratory Corporation of America Holdings, 1120 Main Street,
Southaven, MS 38671, 866-827-8042/800-233-6339. (Formerly: LabCorp
Occupational Testing Services, Inc.; MedExpress/National Laboratory
Center).
LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa,
KS 66219, 913-888-3927/800-873-8845. (Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division
of LabOne, Inc.).
Marshfield Laboratories, Forensic Toxicology Laboratory, 1000 North
Oak Ave., Marshfield, WI 54449, 715-389-3734/800-331-3734.
MAXXAM Analytics Inc.*, 6740 Campobello Road, Mississauga, ON,
Canada L5N 2L8, 905-817-5700. (Formerly: NOVAMANN (Ontario), Inc.).
MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN
55112, 651-636-7466/800-832-3244.
Meriter Laboratories, 36 South Brooks St., Madison, WI 53715, 608-
267-6225. (Formerly: General Medical Laboratories).
MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR
97232, 503-413-5295 / 800-950-5295.
Minneapolis Veterans Affairs Medical Center, Forensic Toxicology
Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612-725-2088.
National Toxicology Laboratories, Inc., 1100 California Ave.,
Bakersfield, CA 93304, 661-322-4250/800-350-3515.
One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff,
Pasadena, TX 77504, 888-747-3774. (Formerly: University of Texas
Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology
Laboratory).
Oregon Medical Laboratories, 123 International Way, Springfield, OR
97477, 541-341-8092.
Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA
91311, 800-328-6942. (Formerly: Centinela Hospital Airport Toxicology
Laboratory).
Pathology Associates Medical Laboratories, 110 West Cliff Dr.,
Spokane, WA 99204, 509-755-8991/800-541-7891x7.
Phamatech, Inc., 10151 Barnes Canyon Road, San Diego, CA 92121,
858-643-5555.
Physicians Reference Laboratory, 7800 West 110th St., Overland
Park, KS 66210, 913-339-0372/800-821-3627.
Quest Diagnostics Incorporated, 3175 Presidential Dr., Atlanta, GA
30340, 770-452-1590/800-729-6432.
[[Page 43293]]
(Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-
Science Laboratories).
Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA
19403, 610-631-4600/877-642-2216. (Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline Bio-Science Laboratories).
Quest Diagnostics Incorporated, 7600 Tyrone Ave., Van Nuys, CA
91405, 866-370-6699/818-989-2521, (Formerly: SmithKline Beecham
Clinical Laboratories).
S.E.D. Medical Laboratories, 5601 Office Blvd., Albuquerque, NM
87109, 505-727-6300/800-999-5227.
South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South
Bend, IN 46601, 574-234-4176 x276.
Southwest Laboratories, 4645 E. Cotton Center Boulevard, Suite 177,
Phoenix, AZ 85040, 602-438-8507/800-279-0027.
Sparrow Health System, Toxicology Testing Center, St. Lawrence
Campus, 1210 W. Saginaw, Lansing, MI 48915, 517-364-7400. (Formerly:
St. Lawrence Hospital & Healthcare System).
St. Anthony Hospital Toxicology Laboratory, 1000 N. Lee St.,
Oklahoma City, OK 73101, 405-272-7052.
Toxicology & Drug Monitoring Laboratory, University of Missouri
Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, MO
65203, 573-882-1273.
Toxicology Testing Service, Inc., 5426 N.W. 79th Ave., Miami, FL
33166, 305-593-2260.
US Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson
St., Fort George G. Meade, MD 20755-5235, 301-677-7085.
*The Standards Council of Canada (SCC) voted to end its Laboratory
Accreditation Program for Substance Abuse (LAPSA) effective May 12,
1998. Laboratories certified through that program were accredited to
conduct forensic urine drug testing as required by U.S. Department of
Transportation (DOT) regulations. As of that date, the certification of
those accredited Canadian laboratories will continue under DOT
authority. The responsibility for conducting quarterly performance
testing plus periodic on-site inspections of those LAPSA-accredited
laboratories was transferred to the U.S. HHS, with the HHS' NLCP
contractor continuing to have an active role in the performance testing
and laboratory inspection processes. Other Canadian laboratories
wishing to be considered for the NLCP may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to be qualified, HHS will
recommend that DOT certify the laboratory (Federal Register, July 16,
1996) as meeting the minimum standards of the Mandatory Guidelines
published in the Federal Register on April 13, 2004 (69 FR 19644).
After receiving DOT certification, the laboratory will be included in
the monthly list of HHS-certified laboratories and participate in the
NLCP certification maintenance program.
Elaine Parry,
Acting Director, Office of Program Services, SAMHSA.
[FR Doc. E7-15149 Filed 8-2-07; 8:45 am]
BILLING CODE 4160-20-P
